Cover Image
市場調查報告書

主要已發展市場的降壓治療:聯合治療的普及擴大彌補主要專利結束的影響

Antihypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries

出版商 GBI Research 商品編碼 305017
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
主要已發展市場的降壓治療:聯合治療的普及擴大彌補主要專利結束的影響 Antihypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries
出版日期: 2014年06月01日 內容資訊: 英文
簡介

主要先進8國市場(美國、英國、法國、德國、西班牙、義大利、日本及加拿大)的降壓治療市值,2013年為400億美金,今後將以年複合成長率0.9%減少,預計至2020年縮小到376億美元。2013-2017年預定以2.6%CAGR成長,不過此後將轉為減少。成長的主要原因,為固定劑量複方藥物的普及擴大、患病者從1億8,100萬人以年複合成長率0.6%增加到1億9,000萬人,及預測開發平台中2個新藥的銷售。可是,在預測期間內主要藥物的專利結束,還有學名藥的普及擴大和診斷率低,市場預計從2017年開始趨向下降。

本報告提供全球主要已發展市場的降壓治療市場的相關調查、疾病概要、治療流程、治療的利用模式、市場規模與預測、主要的成藥、詳細的開發平台分析、預計帶給市場重大影響的主要促進要素與阻礙要素分析,及策略分析等彙整,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 病理學
  • 病因
  • 前兆、症狀
  • 罹患率、併發症
  • 診斷
  • 分類
  • 流行病學
  • 預測
  • 治療、管理

第3章 上市藥

  • 認證藥
  • 功效、安全性比較

第4章 產品平台

  • 整體開發平台(管線)
  • 開發平台分析:各分子類型
  • 開發平台分析:各作用機制
  • 臨床實驗:失敗率
  • 登記患者數、臨床實驗的規模
  • 臨床實驗的繼續期間
  • 開發平台的有潛力候補藥

第5章 市場預測

  • 簡介
  • 全球市場
  • 北美
  • 歐洲的主要5國市場
  • 日本
  • 促進要素、阻礙要素

第6章 契約、策略性整合

  • 授權協定
  • 共同開發協定

第7章 附錄

圖表清單

目錄
Product Code: GBIHC333MR

GBI Research, the leading business intelligence provider, has released its latest research, "Antihypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries", which provides in-depth analysis of hypertension therapeutics market within the eight major geographies of the US, the top five European countries (the UK, France, Germany, Spain and Italy), Japan and Canada. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The value of the hypertension market in the major developed markets amounted to an estimated $40.0 billion in 2013 and is expected to decline during the forecast period at a negative Compound Annual Growth Rate (CAGR) of 0.9% to $37.6 billion in 2020, with growth expected from 2013 to 2017 at a CAGR of 2.6% and a decline thereafter. The initial growth will be due to the increased penetration of fixed-dose combination drugs (Amturnide, Exforge Tribenzor, Azor, Tekturna HCT, Edarbyclor, Twynsta, Benicar HCT, Micardis Plus, Tekamlo, Valturna), a rise in the prevalence population from 181 million to 190 million at a CAGR of 0.6%, and two new expected launches in the pipeline (azilsartan + amlodipine, and AHU377+ valsartan). However, due to the expiry of the exclusivity of major drugs both before and during the forecast period (Cozaar in 2010; Diovan, Avapro and Atacand in 2012; Exforge in 2014; Benicar in 2016; and Tekturna and Tekturna HCT in 2018), increased generic penetration and a low diagnosis rate, the market will decline from 2017.

Market to Decline due to Key Patent Expiries

The global anti-hypertensives market is expected to decline during the forecast period at a negative Compound Annual Growth Rate (CAGR) of 0.9% from $40 billion in 2013 to $37.6 billion in 2020, with growth expected from 2013 to 2017 at a CAGR of 2.6% and a decline thereafter. The initial growth will be due to the increased penetration of fixed-dose combination drugs (Amturnide, Exforge Tribenzor, Azor, Tekturna HCT, Edarbyclor, Twynsta, Benicar HCT, Micardis Plus, Tekamlo, Valturna), a rise in the prevalence population from 181 million to 190 million at a CAGR of 0.6%, and two new expected launches in the pipeline (azilsartan + amlodipine, and AHU377+ valsartan). However, due to the expiry of the exclusivity of major drugs both before and during the forecast period (Cozaar in 2010; Diovan, Avapro and Atacand in 2012; Exforge in 2014; Benicar in 2016; and Tekturna and Tekturna HCT in 2018), increased generic penetration and a low diagnosis rate, the market will decline from 2017. Hypertension is a chronic disease and so its management required prolonged treatment. The management of hypertension requires prolonged treatment as it is a chronic disease, ultimately ensuring market stability despite generic erosion.

Anti-Hypertensives Pipeline: Limited Scope

Most of the drugs in the anti-hypertensives pipeline are generics (77%), and only 20% of molecules are novel drug candidates. The novel approach is limited to a few targets such as nondihydropyridine dual L/T-type calcium channel blockers (ACT-280778), Rho-associated kinase inhibitors (AN-3485), and vitamin D receptor agonists (CARD-024), to name a few. Novartis' AHU-377, a novel molecule that functions as a Neutral Endopeptidase Inhibitor (NEP), is currently in Phase III as a combination drug with Novartis' blockbuster valsartan. Most of the drug dosages in the anti-hypertension market comprise one oral tablet once daily.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the hypertension in the major developed markets.The report includes -

  • Disease overview, as well as treatment algorithms and treatment use patterns
  • Market size and forecast for the hypertension market from 2013-2020
  • Major marketed products for hypertension along with a heat map of product performance
  • In-depth pipeline analysis for global pipeline in hypertension along with clinical trial failure rate analysis
  • Key drivers and restraints that have had and are expected to have a significant impact upon the market
  • Key licensing and co-development agreements that could have impact on growth trends

Reasons to buy

  • The report will enhance your decision-making capability by allowing you to -
  • Align your product portfolio to the markets with high growth potential
  • Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
  • Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the hypertension therapeutics market
  • Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Pathophysiology
  • 2.2. Etiology
  • 2.3. Signs and Symptoms
  • 2.4. Co-Morbidities and Complications
  • 2.5. Diagnosis
    • 2.5.1. Office Blood Pressure Monitoring
    • 2.5.2. Ambulatory Blood Pressure Monitoring
    • 2.5.3. Home Blood Pressure Monitoring
    • 2.5.4. Miscellaneous Methods
    • 2.5.5. Diagnosis of Target Organ Damage
    • 2.5.6. Diagnosis of Hypertension in Pregnancy
  • 2.6. Classification
  • 2.7. Epidemiology
  • 2.8. Prognosis
  • 2.9. Treatment and Management
    • 2.9.1. Treatment Strategy

3. Marketed Products

  • 3.1. Approved Products
    • 3.1.1. Norvasc (amlodipine besylate) - Pfizer
    • 3.1.2. Micardis (telmisartan) - Boehringer Ingelheim
    • 3.1.3. Tekturna (aliskiren) - Novartis/Speedel
    • 3.1.4. Benicar (olmesartan medoxomil) - Daiichi Sankyo
    • 3.1.5. Diovan (valsartan) - Novartis
    • 3.1.6. Cozaar (losartan) - Merck
    • 3.1.7. Exforge (amlodipine + valsartan) - Novartis
  • 3.2. Comparative Efficacy and Safety

4. Product Pipeline

  • 4.1. Overall Pipeline
  • 4.2. Pipeline Analysis by Molecules Type
  • 4.3. Pipeline Analysis by Mechanism of Action Type
  • 4.4. Clinical Trial Failure Rate
  • 4.5. Patient Enrollment and Clinical Trial Size
  • 4.6. Clinical Trial Duration
  • 4.7. Promising Drug Candidates in Pipeline
    • 4.7.1. LCZ696(AHU-377 + valsartan) - Novartis

5. Market Forecast

  • 5.1. Introduction
  • 5.2. Global Market
  • 5.3. North America
    • 5.3.1. Treatment Usage Patterns
    • 5.3.2. Annual Cost of Therapy
    • 5.3.3. Market Revenue
  • 5.4. Top Five European Countries
    • 5.4.1. Treatment Usage Patterns
    • 5.4.2. Annual Cost of Therapy
    • 5.4.3. Market Revenue
  • 5.5. Japan
    • 5.5.1. Treatment Usage Patterns
    • 5.5.2. Annual Cost of Therapy
    • 5.5.3. Market Revenue
  • 5.6. Drivers and Barriers
    • 5.6.1. Drivers
    • 5.6.2. Barriers

6. Deals and Strategic Consolidations

  • 6.1. Licensing Deals
    • 6.1.1. Bristol-Myers Squibb Enters into Licensing Agreement with Kyowa Hakko Kirin for Coniel in China
    • 6.1.2. Takeda Pharma Enters into Licensing Agreement with Arbor Pharma for Edarbi and Edarbyclor
    • 6.1.3. Lorus Therapeutics Enters into Licensing Agreement with Zor Pharma
    • 6.1.4. Nippon Shinyaku Signs Licensing Agreement with Eli Lilly
  • 6.2. Co-development Deals
    • 6.2.1. AnGes Enters into Co-development Agreement with BioLeaders for Hypertension Vaccine
    • 6.2.2. Takeda Enters into Co-development Agreement with Covance
    • 6.2.3. Boehringer Ingelheim Enters into an Agreement with Vitae Pharma
    • 6.2.4. NicOx Expands Research Collaboration with Merck

7. Appendix

  • 7.1. Market Forecasts to 2020
  • 7.2. All Pipeline Drugs by Phase
    • 7.2.1. Discovery
    • 7.2.2. Preclinical
    • 7.2.3. Phase I
    • 7.2.4. Phase II
    • 7.2.5. Phase III
  • 7.3. Abbreviations
  • 7.4. References
  • 7.5. Methodology
    • 7.5.1. Coverage
    • 7.5.2. Secondary Research
    • 7.5.3. Primary Research
    • 7.5.4. Therapeutic Landscape
    • 7.5.5. Geographical Landscape
    • 7.5.6. Pipeline Analysis
  • 7.6. Expert Panel Validation
  • 7.7. Contact Us
  • 7.8. Disclaimer

List of Tables

  • Table 1: Anti-Hypertensives Market, Possible Co-Morbidities
  • Table 2: Anti-Hypertensives Market, Blood Pressure Classification in Adults
  • Table 3: Anti-Hypertensives Market, Prevalence Rate (%)
  • Table 4: Anti-Hypertensives Market, Initiation of Treatment
  • Table 5: Anti-Hypertensives Market, Lifestyle Management
  • Table 6: Anti-Hypertensives Market, Major Developed Market, Forecast Data, 2013-2020
  • Table 7: Anti-Hypertensives Market, US, Forecast Data, 2013-2020
  • Table 8: Anti-Hypertensives Market, UK, Forecast Data, 2013-2020
  • Table 9: Anti-Hypertensives Market, France, Forecast Data, 2013-2020
  • Table 10: Anti-Hypertensives Market, Germany, Forecast Data, 2013-2020
  • Table 11: Anti-Hypertensives Market, Italy, Forecast Data, 2013-2020
  • Table 12: Anti-Hypertensives Market, Spain, Forecast Data, 2013-2020
  • Table 13: Anti-Hypertensives Market, Japan, Forecast Data, 2013-2020
  • Table 14: Anti-Hypertensives Market, Canada, Forecast Data, 2013-2020
  • Table 15: Anti-Hypertensives Market, Global, Developmental Pipeline, Discovery Phase
  • Table 16: Anti-Hypertensives Market, Global, Developmental Pipeline, Preclinical Phase
  • Table 17: Anti-Hypertensives Market, Global, Developmental Pipeline, Phase I
  • Table 18: Anti-Hypertensives Market, Developmental Pipeline, Phase II
  • Table 19: Anti-Hypertensives Market, Developmental Pipeline Phase III, 2013
  • Table 20: Anti-Hypertensives Market, Therapeutics, Abbreviations

List of Figures

  • Figure 1: Anti-Hypertensives Market, Global, Prevalence Rate (%), 2007-2010
  • Figure 2: Anti-Hypertensives Market, Treatment Algorithm, 2013
  • Figure 3: Anti-Hypertensives Market, Global, Norvasc (amlodipine besylate) Revenue ($bn), 2005-2013
  • Figure 4: Anti-Hypertensives Market, Global, Micardis (telmisartan), Revenue ($bn), 2005-2013
  • Figure 5: Anti-Hypertensives Market, Global, Tekturna (aliskiren) Revenue ($m), 2007-2013
  • Figure 6: Anti-Hypertensives Market, Global, Benicar (olmesartan), Revenue ($bn), 2005-2013
  • Figure 7: Anti-Hypertensives Market, Global, Diovan (valsartan) Revenue ($bn), 2005-2013
  • Figure 8: Anti-Hypertensives Market, Global, Cozaar (losartan), Revenue ($bn), 2005-2013
  • Figure 9: Anti-Hypertensives Market, Global, Exforge (amlodipine + valsartan), Revenue ($bn), 2007-2013
  • Figure 10: Anti-Hypertensives Market, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2013
  • Figure 11: Anti-Hypertensives Market, Global, Pipeline Distribution by Stage, Program Type and Route of Administration, 2013
  • Figure 12: Anti-Hypertensives Market, Global, Pipeline by Molecule Type and Stage of Development, 2013
  • Figure 13: Anti-Hypertensives Market, Global, Pipeline by Mechanism of Action, 2013
  • Figure 14: Anti-Hypertensives Market, Global, Pipeline by Mechanism of Action, Molecule Type and Stage of Development, 2013
  • Figure 15: Anti-Hypertensives Market, Global, Clinical Trial Failure Rate (%), 2013
  • Figure 16: Anti-Hypertensives Market, Global, Clinical Trial Failure Rate (%), 2006-2013
  • Figure 17: Anti-Hypertensives Market, Global, Clinical Trial Size (Participants), 2013
  • Figure 18: Anti-Hypertensives Market, Global, Pipeline Clinical Trial Duration (Months), 2013
  • Figure 19: Anti-Hypertensives Market, Global, Treatment Usage Patterns and Market Revenue ($bn), 2013-2020
  • Figure 20: Anti-Hypertensives Market, US and Canada, Treatment Usage Patterns, 2013-2020
  • Figure 21: Anti-Hypertensives Market, US and Canada, Annual Cost of Therapy ($), 2013-2020
  • Figure 22: Anti-Hypertensives Market, US and Canada, Market Revenue ($bn), 2013-2020
  • Figure 23: Anti-Hypertensives Market, Top Five European Markets, Treatment Usage Patterns, 2013-2020
  • Figure 24: Anti-Hypertensives Market, Top Five European Markets, Annual Cost of Therapy ($), 2013-2020
  • Figure 25: Anti-Hypertensives Market, Top Five European Markets, Market Revenue ($bn), 2013-2020
  • Figure 26: Anti-Hypertensives Market, Japan, Treatment Usage Patterns, 2013-2020
  • Figure 27: Anti-Hypertensives Market, Japan, Annual Cost of Therapy ($), 2013-2020
  • Figure 28: Anti-Hypertensives Market, Japan, Market Revenue ($bn), 2013-2020
  • Figure 29: Anti-Hypertensives Market, Global Deals by Value, Year and Stage of Development, 2006-2013
  • Figure 30: Anti-Hypertensives Market, Global, Deals by Phase, Molecule Type and Mechanism of Action, 2006-2013
  • Figure 31: Anti-Hypertensives Market, Global, Licensing Deals by Geography, 2006-2013
  • Figure 32: Anti-Hypertensives Market, Global, Co-Development Deals by Region, Value ($m) and Year, 2006-2013
  • Figure 33: GBI Research Market Forecasting Model
Back to Top